Plasma 25-hydroxyvitamin D levels and survival in stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)

To assess whether higher plasma 25-hydroxyvitamin D (25[OH]D) are associated with improved outcomes in colon cancer and whether circulating inflammatory cytokines mediate such association. Plasma samples were collected from 1437 patients with stage III colon cancer enrolled in a phase III randomized...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2023-07, Vol.29 (14), p.2621-2630
Main Authors: Wang, Qiao-Li, Ma, Chao, Yuan, Chen, Shi, Qian, Wolpin, Brian M, Zhang, Yin, Fuchs, Charles S, Meyer, Jeffrey, Zemla, Tyler, Cheng, En, Kumthekar, Priya, Guthrie, Katherine A, Couture, Felix, Kuebler, Philip, Kumar, Pankaj, Tan, Benjamin, Krishnamurthi, Smitha, Goldberg, Richard M, Venook, Alan, Blanke, Charles, Shields, Anthony F, O'Reilly, Eileen M, Meyerhardt, Jeffrey A, Ng, Kimmie
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess whether higher plasma 25-hydroxyvitamin D (25[OH]D) are associated with improved outcomes in colon cancer and whether circulating inflammatory cytokines mediate such association. Plasma samples were collected from 1437 patients with stage III colon cancer enrolled in a phase III randomized clinical trial (CALGB/SWOG 80702) from 2010 to 2015, who were followed until 2020. Cox regressions were used to examine associations between plasma 25(OH)D and disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Mediation analysis was performed for circulating inflammatory biomarkers of CRP, IL-6, and sTNF-R2. Vitamin D deficiency (25(OH)D
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-23-0447